Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Kettering, Ohio.

Sponsor
Cylene Pharmaceuticals
Study ID
NCT01199718
Phase
PHASE1
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CX-4945 — DRUG
    CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.

Study Details

This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.

Key Dates

Start date
Sep 30, 2010
Status verified
Jun 2011
Primary completion
Jun 30, 2011
Completion
Sep 30, 2011

Study Design

Enrollment
22 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CX-4945
    CX-4945 oral formulation

Primary Outcome Measure

Safety [ Time Frame: One year (assessed at Cycle 1). ]

Locations (6)

FacilityCityStateZIPSite coordinators
-KetteringOhio45249
Michelle Owens, RN
[email protected]
Oregon Health Science UniversityPortlandOregon97239
Farnoush Abar, MD
[email protected]
-SpringfieldOregon97477
Jeanne Schaffer, RN
[email protected]
-GreenvilleSouth Carolina29605
Jan Kueber, RN
[email protected]
-NorfolkVirginia23502
Gabrielle Geho, RN
[email protected]
-YakimaWashington98902

Find similar trials in Kettering, OH

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Oregon Health Science University· Portland, OR

Related Studies